<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00807937</url>
  </required_header>
  <id_info>
    <org_study_id>D1140C00014</org_study_id>
    <nct_id>NCT00807937</nct_id>
  </id_info>
  <brief_title>Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325</brief_title>
  <official_title>A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase II Study of 2 Oral Dose Groups of AZD7325, With a Lorazepam Arm, in Subjects With Generalized Anxiety Disorder (GAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine whether AstraZeneca's drug AZD7325 is safe
      and effective in the treatment of generalized anxiety disorder.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>HAM-A total score 0-56 units, 14 questions scored on scale of 0-4 (0= Not present, 4=Very severe) . Higher HAM-A scores indicate higher levels of anxiety Change : score at week 4 minus score at randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hospital Anxiety and Depression Scale for Anxiety (HADS-A) Total Score</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>HADS-A total score 0-21 units, 0 is the best, Higher total scores indicate a higher severity of the mood or anxiety disorder Change : score at week 4 minus score at randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Psychic Anxiety Factor as Measured by HAM-A Psychic Cluster Score</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>The HAM-A psychic anxiety cluster score 0-28 units consists of 7 questions scored on scale of 0-4 (0=Not present, 4=Very severe) . Higher scores indicate higher levels of psychic anxiety disorder.
Change: score at week 4 minus score at randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Somatic Symptoms as Measured by HAM-A Somatic Cluster Score</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>The HAM-A Somatic cluster score 0-28 units consists of 7 questions scored on scale of 0-4 (0=Not present, 4=Very severe ) . Higher scores indicate higher levels of psychic anxiety disorder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) Percent Maximum Total Score</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>Q-LES-Q total score is the sum of the first 14 times of Q-LES-Q, and this total score is converted to a % maximum total score by : Q-LES-Q total score /70 x 100%, Larger values indicate a higher perceived quality of life enjoyment and satisfaction.
Change : percentage at week 4 minus percentage at randomization</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">369</enrollment>
  <condition>Anxiety Disorders</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD7325 5mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD7325 15mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lorazepam 2mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD7325</intervention_name>
    <description>4 tablets and 1 capsule taken twice a day for 28 days</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD7325</intervention_name>
    <description>4 tablets and 1 capsule taken twice a day for 28 days</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorazepam</intervention_name>
    <description>4 tablets and 1 capsule taken twice a day for 28 days</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 tablets and 1 capsule taken twice a day for 28 days</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent before any study-related procedures start.

          -  The patient is previously diagnosed with Generalized Anxiety Disorder.

          -  The patient has a HADS-A (anxiety) score â‰¥10 at both screening and randomization.

        Exclusion Criteria:

          -  Patient has a lifetime history of schizophrenia or other psychotic disorders

          -  Patient has a history of seizures or seizure disorder.

          -  Patient is pregnant or breast feeding.

          -  Patient has received electroconvulsive treatment (ECT) in the past.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark A. Smith, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Carson</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gainsville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oak Brook</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Schaumburg</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Westminster</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Braintree</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Piscataway</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cedarhurst</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Willoughby</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salem</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bartlett</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2008</study_first_submitted>
  <study_first_submitted_qc>December 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2008</study_first_posted>
  <results_first_submitted>July 29, 2010</results_first_submitted>
  <results_first_submitted_qc>September 16, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 8, 2010</results_first_posted>
  <last_update_submitted>September 16, 2010</last_update_submitted>
  <last_update_submitted_qc>September 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mark A. Smith, MD PhD, Medical Science Director, Emerging Psychiatry</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Generalized Anxiety Disorder</keyword>
  <keyword>GAD</keyword>
  <keyword>Anxiety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lorazepam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>International multi-center study, 43 sites recruited between Dec 2008 and May 2009</recruitment_details>
      <pre_assignment_details>Screening for eligibility and wash-out of restriced medications</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD7325 5 mg</title>
          <description>AZD7325 5 mg twice daily (BID)</description>
        </group>
        <group group_id="P2">
          <title>AZD7325 15 mg</title>
          <description>AZD7325 15 mg twice daily (BID)</description>
        </group>
        <group group_id="P3">
          <title>Lorazepam</title>
          <description>Lorazepam 2 mg twice daily (BID)</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="92"/>
                <participants group_id="P3" count="92"/>
                <participants group_id="P4" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="78"/>
                <participants group_id="P4" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Intake of prohibited medicine</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>All other reasons (not provided)</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD7325 5 mg</title>
          <description>AZD7325 5 mg twice daily (BID)</description>
        </group>
        <group group_id="B2">
          <title>AZD7325 15 mg</title>
          <description>AZD7325 15 mg twice daily (BID)</description>
        </group>
        <group group_id="B3">
          <title>Lorazepam</title>
          <description>Lorazepam 2 mg twice daily (BID)</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="93"/>
            <count group_id="B2" value="92"/>
            <count group_id="B3" value="92"/>
            <count group_id="B4" value="92"/>
            <count group_id="B5" value="369"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18-39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score</title>
        <description>HAM-A total score 0-56 units, 14 questions scored on scale of 0-4 (0= Not present, 4=Very severe) . Higher HAM-A scores indicate higher levels of anxiety Change : score at week 4 minus score at randomization</description>
        <time_frame>Baseline to week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD7325 5 mg</title>
            <description>AZD7325 5 mg twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>AZD7325 15 mg</title>
            <description>AZD7325 15 mg twice daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>Lorazepam</title>
            <description>Lorazepam 2 mg twice daily (BID)</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score</title>
          <description>HAM-A total score 0-56 units, 14 questions scored on scale of 0-4 (0= Not present, 4=Very severe) . Higher HAM-A scores indicate higher levels of anxiety Change : score at week 4 minus score at randomization</description>
          <units>Units on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.1" spread="0.89" lower_limit="0.89"/>
                    <measurement group_id="O2" value="-10.4" spread="0.89" lower_limit="0.89"/>
                    <measurement group_id="O3" value="-10.8" spread="0.88" lower_limit="0.88"/>
                    <measurement group_id="O4" value="-9.5" spread="0.88" lower_limit="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hospital Anxiety and Depression Scale for Anxiety (HADS-A) Total Score</title>
        <description>HADS-A total score 0-21 units, 0 is the best, Higher total scores indicate a higher severity of the mood or anxiety disorder Change : score at week 4 minus score at randomization</description>
        <time_frame>Baseline to week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD7325 5 mg</title>
            <description>AZD7325 5 mg twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>AZD7325 15 mg</title>
            <description>AZD7325 15 mg twice daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>Lorazepam</title>
            <description>Lorazepam 2 mg twice daily (BID)</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hospital Anxiety and Depression Scale for Anxiety (HADS-A) Total Score</title>
          <description>HADS-A total score 0-21 units, 0 is the best, Higher total scores indicate a higher severity of the mood or anxiety disorder Change : score at week 4 minus score at randomization</description>
          <units>Units on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="0.51" lower_limit="0.51"/>
                    <measurement group_id="O2" value="-4.9" spread="0.51" lower_limit="0.51"/>
                    <measurement group_id="O3" value="-5.0" spread="0.51" lower_limit="0.51"/>
                    <measurement group_id="O4" value="-4.5" spread="0.50" lower_limit="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Psychic Anxiety Factor as Measured by HAM-A Psychic Cluster Score</title>
        <description>The HAM-A psychic anxiety cluster score 0-28 units consists of 7 questions scored on scale of 0-4 (0=Not present, 4=Very severe) . Higher scores indicate higher levels of psychic anxiety disorder.
Change: score at week 4 minus score at randomization</description>
        <time_frame>Baseline to week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD7325 5 mg</title>
            <description>AZD7325 5 mg twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>AZD7325 15 mg</title>
            <description>AZD7325 15 mg twice daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>Lorazepam</title>
            <description>Lorazepam 2 mg twice daily (BID)</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Psychic Anxiety Factor as Measured by HAM-A Psychic Cluster Score</title>
          <description>The HAM-A psychic anxiety cluster score 0-28 units consists of 7 questions scored on scale of 0-4 (0=Not present, 4=Very severe) . Higher scores indicate higher levels of psychic anxiety disorder.
Change: score at week 4 minus score at randomization</description>
          <units>Units on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="0.51" lower_limit="0.51"/>
                    <measurement group_id="O2" value="-5.7" spread="0.51" lower_limit="0.51"/>
                    <measurement group_id="O3" value="-6.0" spread="0.51" lower_limit="0.51"/>
                    <measurement group_id="O4" value="-5.1" spread="0.51" lower_limit="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Somatic Symptoms as Measured by HAM-A Somatic Cluster Score</title>
        <description>The HAM-A Somatic cluster score 0-28 units consists of 7 questions scored on scale of 0-4 (0=Not present, 4=Very severe ) . Higher scores indicate higher levels of psychic anxiety disorder.</description>
        <time_frame>Baseline to week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD7325 5 mg</title>
            <description>AZD7325 5 mg twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>AZD7325 15 mg</title>
            <description>AZD7325 15 mg twice daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>Lorazepam</title>
            <description>Lorazepam 2 mg twice daily (BID)</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Somatic Symptoms as Measured by HAM-A Somatic Cluster Score</title>
          <description>The HAM-A Somatic cluster score 0-28 units consists of 7 questions scored on scale of 0-4 (0=Not present, 4=Very severe ) . Higher scores indicate higher levels of psychic anxiety disorder.</description>
          <units>Units on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="0.43" lower_limit="0.43"/>
                    <measurement group_id="O2" value="-4.7" spread="0.43" lower_limit="0.43"/>
                    <measurement group_id="O3" value="-4.9" spread="0.43" lower_limit="0.43"/>
                    <measurement group_id="O4" value="-4.3" spread="0.43" lower_limit="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) Percent Maximum Total Score</title>
        <description>Q-LES-Q total score is the sum of the first 14 times of Q-LES-Q, and this total score is converted to a % maximum total score by : Q-LES-Q total score /70 x 100%, Larger values indicate a higher perceived quality of life enjoyment and satisfaction.
Change : percentage at week 4 minus percentage at randomization</description>
        <time_frame>Baseline to week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD7325 5 mg</title>
            <description>AZD7325 5 mg twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>AZD7325 15 mg</title>
            <description>AZD7325 15 mg twice daily (BID)</description>
          </group>
          <group group_id="O3">
            <title>Lorazepam</title>
            <description>Lorazepam 2 mg twice daily (BID)</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) Percent Maximum Total Score</title>
          <description>Q-LES-Q total score is the sum of the first 14 times of Q-LES-Q, and this total score is converted to a % maximum total score by : Q-LES-Q total score /70 x 100%, Larger values indicate a higher perceived quality of life enjoyment and satisfaction.
Change : percentage at week 4 minus percentage at randomization</description>
          <units>percentage</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.79" spread="1.339" lower_limit="1.339"/>
                    <measurement group_id="O2" value="9.04" spread="1.338" lower_limit="1.338"/>
                    <measurement group_id="O3" value="7.46" spread="1.318"/>
                    <measurement group_id="O4" value="6.95" spread="1.317" lower_limit="1.317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZD7325 5 mg</title>
          <description>AZD7325 5 mg twice daily (BID)</description>
        </group>
        <group group_id="E2">
          <title>AZD7325 15 mg</title>
          <description>AZD7325 15 mg twice daily (BID)</description>
        </group>
        <group group_id="E3">
          <title>Lorazepam</title>
          <description>Lorazepam 2 mg twice daily (BID)</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="51" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Feeling Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Feeling Drunk</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Euphoric Mood</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Mood Altered</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

